107 related articles for article (PubMed ID: 28807460)
1. Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial.
Lyubarova R; Robinson JG; Miller M; Simmons DL; Xu P; Abramson BL; Elam MB; Brown TM; McBride R; Fleg JL; Desvigne-Nickens P; Ayenew W; Boden WE;
J Clin Lipidol; 2017; 11(5):1201-1211. PubMed ID: 28807460
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.
Probstfield JL; Boden WE; Anderson T; Branch K; Kashyap M; Fleg JL; Desvigne-Nickens P; McBride R; McGovern M;
J Clin Lipidol; 2018; 12(6):1413-1419. PubMed ID: 30131256
[TBL] [Abstract][Full Text] [Related]
3. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
[TBL] [Abstract][Full Text] [Related]
4. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
5. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
[TBL] [Abstract][Full Text] [Related]
6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
7. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2.
Taylor AJ; Zhu D; Sullenberger LE; Lee HJ; Lee JK; Grace KA
Vasc Health Risk Manag; 2007; 3(1):159-64. PubMed ID: 17583186
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach.
Santilli F; D'Ardes D; Guagnano MT; Davi G
Curr Med Chem; 2017; 24(24):2602-2627. PubMed ID: 28699503
[TBL] [Abstract][Full Text] [Related]
9. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature.
Pucci G; Alcidi R; Tap L; Battista F; Mattace-Raso F; Schillaci G
Pharmacol Res; 2017 Jun; 120():34-42. PubMed ID: 28300617
[TBL] [Abstract][Full Text] [Related]
10. Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database.
Sazonov V; Beetsch J; Phatak H; Wentworth C; Evans M
Atherosclerosis; 2010 Jan; 208(1):210-6. PubMed ID: 19766999
[TBL] [Abstract][Full Text] [Related]
11. Associations of metabolic syndrome and its components with cardiovascular outcomes among non-diabetic patients undergoing maintenance peritoneal dialysis.
Liao CT; Kao TW; Chou YH; Wu MS; Chen YM; Chuang HF; Hung KY; Chu TS; Wu KD; Tsai TJ
Nephrol Dial Transplant; 2011 Dec; 26(12):4047-54. PubMed ID: 21565947
[TBL] [Abstract][Full Text] [Related]
12. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome.
Mielniczuk LM; Pfeffer MA; Lewis EF; Blazing MA; de Lemos JA; Shui A; Mohanavelu S; Califf RM; Braunwald E
Am Heart J; 2008 Apr; 155(4):725-31. PubMed ID: 18371483
[TBL] [Abstract][Full Text] [Related]
13. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.
Sigvant B; Kragsterman B; Falkenberg M; Hasvold P; Johansson S; Thuresson M; Nordanstig J
J Vasc Surg; 2016 Oct; 64(4):1009-1017.e3. PubMed ID: 27209402
[TBL] [Abstract][Full Text] [Related]
14. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
15. The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial: to believe or not to believe?
Nicholls SJ
J Am Coll Cardiol; 2012 Jun; 59(23):2065-7. PubMed ID: 22520248
[No Abstract] [Full Text] [Related]
16. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
Jacobson TA; Wertz DA; Hoy T; Kuznik A; Grochulski D; Cziraky M
Mayo Clin Proc; 2008 Dec; 83(12):1316-25. PubMed ID: 19046550
[TBL] [Abstract][Full Text] [Related]
17. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
Schwartz GG; Abt M; Bao W; DeMicco D; Kallend D; Miller M; Mundl H; Olsson AG
J Am Coll Cardiol; 2015 Jun; 65(21):2267-75. PubMed ID: 26022813
[TBL] [Abstract][Full Text] [Related]
18. Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Diabetes Obes Metab; 2016 Apr; 18(4):384-91. PubMed ID: 26679079
[TBL] [Abstract][Full Text] [Related]
19. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
